Abstract：Objective To analyze the clinical value of atorvastatin calcium combined with fenofibrate in the treatment of coronary atherosclerotic heart disease（CHD）. Methods A total of 82 cases of CHD patient were selected and divided into a combination group（n=41）and a single group（n=41）by random number table method.The single group was treated with atorvastatin calcium,and the combined group was treated with fenofibrate on the basis of a single group.The therapeutic effect,blood lipid levels [total cholesterol（TC）,high-density lipoprotein cholesterol（HDL-C）,triglyceride（TG）],carotid intimax-media thickness（IMT）,vascular endothelial function [nitric oxide（NO）,endothelin-1（ET-1）],cardiac function [left ventricular end-systolic diameter（LVESD）,and left ventricular ejection fraction（LVEF）] were compared between the two groups Number and the incidence of adverse reactions. Results The total effective rate of the combination group95.12%（39/41）was higher than that of the single group 80.49%（33/41）（P<0.05）.After treatment,the TC and TG levels in the combination group were lower than those in the single group,and the HDL-C level was higher than those in the single group（P<0.05）.After treatment,the level of carotid IMT in the combination group was lower than that in the single group（P<0.05）.After treatment,the ET-1 level in the combination group was lower than that in the single group,and the NO level was higher than that in the single group（P<0.05）.After treatment,the LVEF level in the combination group was higher than that in the single group,and the LVESD level was lower than that in the single group（P<0.05）.There was no significant difference in adverse reactions between the two groups（P>0.05）. Conclusion Fenofibrate combined with atorvastatin calcium in the treatment of CHD patients can improve the efficacy,reduce the blood lipid levels and carotid IMT thickness,and improve the vascular endothelial function and cardiac function,which is safe and reliable.
2024, Vol. 44 
